// App-Quantinova.ai

2547.0 : Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG03.01) randomized clinical trial.

Researchers

Presenter

  • Andrew Jehyun Song

Principal Investigators

  • Keyue Ding

  • Normand Laperriere

  • James R. Perry

  • Warren P. Mason

  • Chad Winch

  • Christopher J. O'Callaghan

  • Johan Menten

  • Alba Ariela Brandes

  • Claire Phillips

  • Michael F. Fay

  • Ryo Nishikawa

  • David Osoba

  • Gregory Cairncross

  • Wilson Roa

  • Wolfgang Wick

  • Wenyin Shi

Medical Centers

  • Sidney Kimmel Cancer Center, Philadelphia, PA.

  • Canadian Cancer Trials Group, Kingston, ON, Canada

  • Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada

  • Sunnybrook Health Sciences Centre, Toronto, ON, Canada

  • Canadian Cancer Trials Group, Kingston, ON, Canada

  • Queen's University, Canadian Cancer Trials Group, Kingston, ON, Canada

  • AUSL-IRCCS Institute of Neurological Sciences, Bologna, Italy

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Genesis Cancer Care, Perth, Australia

  • Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center, Saitama, Japan

  • QOL Consulting, West Vancouver, BC, Canada

  • Charbonneau Cancer Institute at the University of Calgary, Calgary, AB, Canada

  • Cross Cancer Institute, Edmonton, AB, Canada

  • National Ctr. for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany

  • Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • N/A

Biomarkers

  • O-6-methylguanine DNA methyltransferase

Drug/Treatment

  • Temozolomide

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • NCT00482677

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved